Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Stephan Vagner

Showing results (21-30 of 22) with videos related to

Pageof 3
Sort By:
You have reached the last page of results.This site can display upto 22 results.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 19, 2011
Skin tumors induced by sorafenib; paradoxic RAS-RAF pathway activation and oncogenic mutations of HRAS, TP53, and TGFBR1Jean Philippe Arnault, Christine Mateus, Bernard Escudier, et al.
Nature|March 28, 2014
Reversible and adaptive resistance to BRAF(V600E) inhibition in melanomaChong Sun, Liqin Wang, Sidong Huang, et al.
Pageof 3

Showing results (21-30 of 22) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 22 results.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 19, 2011
Skin tumors induced by sorafenib; paradoxic RAS-RAF pathway activation and oncogenic mutations of HRAS, TP53, and TGFBR1Jean Philippe Arnault, Christine Mateus, Bernard Escudier, et al.
Nature|March 28, 2014
Reversible and adaptive resistance to BRAF(V600E) inhibition in melanomaChong Sun, Liqin Wang, Sidong Huang, et al.
Pageof 3